Kura Oncology to Participate in Stifel Targeted Oncology Forum
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing […]
TSX News -
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
Q1 2024 consolidated revenue of $16.2 million Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA1 FY2024 revenue guidance confirmed […]
MariMed Partners with Iconic Boston Music Venues
NORWOOD, Mass., April 10, 2024 (GLOBE NEWSWIRE) — Leading multi-state cannabis operator MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD) today […]
TSX News -
Amerigo Reports Strong Q1-2024 Operational Results
Q1-2024 copper production of 16.0 million pounds, 2% over guidance Q1-2024 normalized cash cost1of $1.89 per pound, beating guidance by […]
Koryx Copper Intersects 98.00 M @ 0.43% Cu Eq, Including 4 M @ 1.12% Cu Eq and 2 M @ 1.47% Cu Eq
Significant copper and molybdenum intersections include: HM17: 0.93% CuEq over 12 meters from near surface including 4 m @ 1.52% […]
Revival Gold Agrees to Acquire Ensign Minerals and Announces Concurrent C$7 Million Equity Financing
Creating One of the Largest Gold Development Companies in the United States with an Enhanced Platform for Heap Leach GoldProduction from […]
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Vancouver, Canada, April 10, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “company”), a […]
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
LOS ALTOS, Calif., April 10, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for […]
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused […]
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumab HB-200 program receives […]
